Harvard Bioscience Inc.’s board of directors this week elected Jeffrey A. Duchemin as chief executive of the Holliston company. The interim CEO, David Green, will continue as president until the spin-off of the regenerative medicine subsidiary, which Green will head. Most recently, Duchemin was global business director for Corning Life Sciences Full story for BostonGlobe.com subscribers.
This is a summary. To read the whole story subscribe to BostonGlobe.com
© Copyright 2014 Globe Newspaper Company.
Get the full story with unlimited access to BostonGlobe.com. Just 99¢ for 4 weeks.